Toxic effects of ultraviolet radiation on the skin.

Ultraviolet (UV) irradiation present in sunlight is an environmental human carcinogen. The toxic effects of UV from natural sunlight and therapeutic artificial lamps are a major concern for human health. The major acute effects of UV irradiation on normal human skin comprise sunburn inflammation (erythema), tanning, and local or systemic immunosuppression. At the molecular level, UV irradiation causes DNA damage such as cyclobutane pyrimidine dimers and (6-4) photoproducts, which are usually repaired by nucleotide excision repair (NER). Chronic exposure to UV irradiation leads to photoaging, immunosuppression, and ultimately photocarcinogenesis. Photocarcinogenesis involves the accumulation of genetic changes, as well as immune system modulation, and ultimately leads to the development of skin cancers. In the clinic, artificial lamps emitting UVB (280-320 nm) and UVA (320-400 nm) radiation in combination with chemical drugs are used in the therapy of many skin diseases including psoriasis and vitiligo. Although such therapy is beneficial, it is accompanied with undesirable side effects. Thus, UV radiation is like two sides of the same coin--on one side, it has detrimental effects, and on the other side, it has beneficial effects.

[1]  R. Anderson,et al.  ERYTHEMA AND MELANOGENESIS ACTION SPECTRA OF NORMAL HUMAN SKIN * , 1982, Photochemistry and photobiology.

[2]  S. Kawanishi,et al.  8-Hydroxydeoxyguanosine formation at the 5' site of 5'-GG-3' sequences in double-stranded DNA by UV radiation with riboflavin. , 1993, The Journal of biological chemistry.

[3]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[4]  R. V. van Gurp,et al.  Suppression of delayed-type hypersensitivity to histocompatibility antigens by ultraviolet radiation. , 1987, Immunology.

[5]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[6]  R. Marks,et al.  Epidemiology of melanoma , 2000, Clinical and experimental dermatology.

[7]  A. Lehmann.  Nucleotide excision repair and the link with transcription. , 1995, Trends in biochemical sciences.

[8]  C. Bucana,et al.  Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. P. Pasker-De Jong,et al.  Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. , 1999, Archives of dermatology.

[10]  N. Soter,et al.  Acute effects of ultraviolet radiation on the skin. , 1990, Seminars in dermatology.

[11]  J. Dickinson,et al.  Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. , 1996, Cancer research.

[12]  L. Applegate,et al.  Identification of the molecular target for the suppression of contact hypersensitivity by ultraviolet radiation , 1989, The Journal of experimental medicine.

[13]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[14]  L. Cerroni,et al.  p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). , 1997, The Journal of investigative dermatology.

[15]  Thomas A. Luger,et al.  Ultraviolet Light Induces Apoptosis via Direct Activation of CD95 (Fas/APO-1) Independently of Its Ligand CD95L , 1998, The Journal of cell biology.

[16]  R. Stern,et al.  Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. A case report and the experience of the PUVA Follow-up Study. , 1988, Journal of the American Academy of Dermatology.

[17]  Y. Matsumura,et al.  High prevalence of mutations in the p53 gene in poorly differentiated squamous cell carcinomas in xeroderma pigmentosum patients. , 1995, The Journal of investigative dermatology.

[18]  G F Gerberick,et al.  Cumulative effects from repeated exposures to suberythemal doses of UVB and UVA in human skin. , 1995, Journal of the American Academy of Dermatology.

[19]  D. Smedley,et al.  Characterization of chromosome 1 abnormalities in malignant melanomas , 2000, Genes, chromosomes & cancer.

[20]  G. Plewig,et al.  PUVA inhibits DNA replication, but not gene transcription at nonlethal dosages. , 1998, The Journal of investigative dermatology.

[21]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[22]  A. Kopf,et al.  Risk factors for the development of malignant melanoma--I: Review of case-control studies. , 1988, The Journal of dermatologic surgery and oncology.

[23]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[24]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[25]  M. Kapoor,et al.  p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells , 2002, Cell Death and Differentiation.

[26]  H. Ananthaswamy,et al.  Molecular mechanisms of photocarcinogenesis. , 2002, Frontiers in bioscience : a journal and virtual library.

[27]  L. Dubertret,et al.  P16 UV mutations in human skin epithelial tumors , 1999, Oncogene.

[28]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[29]  G. T. Bowden,et al.  Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Brodland,et al.  The Epidemiology of Skin Cancer , 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[31]  H. Kerl,et al.  High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients. , 2003, The Journal of investigative dermatology.

[32]  T. Fitzpatrick.  Ultraviolet-induced pigmentary changes: benefits and hazards. , 1986, Current problems in dermatology.

[33]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[34]  B. Gilchrest,et al.  Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. , 1997, Experimental cell research.

[35]  S. Ullrich.  PHOTOIMMUNE SUPPRESSION AND PHOTOCARCINOGENESIS , 2002 .

[36]  G. Wahl,et al.  Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Morison Wl.  In vivo effects of psoralens plus longwave ultraviolet radiation on immunity. , 1984 .

[38]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[39]  I. Tessman,et al.  Mechanism of SOS mutagenesis of UV-irradiated DNA: mostly error-free processing of deaminated cytosine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  The genetics of hereditary melanoma and nevi , 1999, Cancer.

[41]  B. Berne,et al.  PUVA and cancer: a large-scale epidemiological study , 1991, The Lancet.

[42]  A. MonemElMofty.  A preliminary clinical report on the treatment of leucodermia with Ammi majus Linn. , 1948 .

[43]  M. Greene,et al.  Developmental defects in gorlin syndrome related to a putative tumor suppressor gene on chromosome 9 , 1992, Cell.

[44]  J. Ferguson,et al.  311 nm UVB phototherapy—an effective treatment for psoriasis , 1988, The British journal of dermatology.

[45]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[46]  Yusuke Nakamura,et al.  A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis , 1997, Oncogene.

[47]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[48]  P. Norris,et al.  Persistent skin pain after PUVA , 1987, Clinical and experimental dermatology.

[49]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[50]  C. Gregory.  Phagocytic clearance of apoptotic cells: food for thought , 1998, Cell Death and Differentiation.

[51]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. MONEM EL MOFTY.  A preliminary clinical report on the treatment of leucodermia with Ammi majus Linn. , 1948, The Journal of the Egyptian Medical Association.

[53]  D. Whiteman,et al.  Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies , 2004, Cancer Causes & Control.

[54]  E. Sage,et al.  Sequence specificity in photoreaction of various psoralen derivatives with DNA: role in biological activity. , 1988, Biochemistry.

[55]  Thomas B. Fitzpatrick,et al.  Dermatology in general medicine , 1971 .

[56]  S. Yuspa,et al.  Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[57]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[58]  L. Staiano‐Coico,et al.  PUVA Treatment Selectively Induces a Cell Cycle Block and Subsequent Apoptosis in Human T‐Lymphocytes , 1996, Photochemistry and photobiology.

[59]  E. Sage,et al.  Damage distribution and mutation spectrum: the case of 8-methoxypsoralen plus UVA in mammalian cells. , 1991, Mutation research.

[60]  M. Barbacid.  ras genes. , 1987, Annual review of biochemistry.

[61]  T. Jacks,et al.  Sunburn and p53 in the onset of skin cancer , 1994, Nature.

[62]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[63]  J. Parrish,et al.  Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA). , 1983, The Journal of investigative dermatology.

[64]  R. Knobler,et al.  CYTOKINE RELEASE BY PERIPHERAL BLOOD MONONUCLEAR CELLS IS AFFECTED BY 8‐METHOXYPSORALEN PLUS UV‐A , 1994, Photochemistry and photobiology.

[65]  R. Stern,et al.  Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. , 1998, Journal of the National Cancer Institute.

[66]  S. Beissert,et al.  Role of immunomodulation in diseases responsive to phototherapy. , 2002, Methods.

[67]  Ian Jackson,et al.  Variants of the melanocyte–stimulating hormone receptor gene are associated with red hair and fair skin in humans , 1995, Nature Genetics.

[68]  J. Mark Elwood,et al.  Melanoma and sun exposure: An overview of published studies , 1997, International journal of cancer.

[69]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[70]  M. Kripke,et al.  Fas ligand: a sensor for DNA damage critical in skin cancer etiology. , 1999, Science.

[71]  B. Vermeer,et al.  Minimising the Risks of PUVA Treatment , 1993, Drug safety.

[72]  M. Kripke,et al.  Suppression of contact hypersensitivity in mice by ultraviolet irradiation is associated with defective antigen presentation. , 1981, Immunology.

[73]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[74]  M. Greene.  The genetics of hereditary melanoma and nevi , 1999 .

[75]  B. Hill,et al.  IMMUNOSUPPRESSIVE DRUG THERAPY AS A POTENTIATOR OF SKIN TUMOURS IN FIVE PATIENTS WITH LYMPHOMA * , 1976, The Australasian journal of dermatology.

[76]  D. Mitchell,et al.  THE BIOLOGY OF THE (6–4) PHOTOPRODUCT , 1989, Photochemistry and photobiology.

[77]  K. Fye,et al.  EFFECTS OF ULTRAVIOLET RADIATION ON THE MITOTIC CYCLE AND DNA, RNA AND PROTEIN SYNTHESIS IN MAMMALIAN EPIDERMIS IN VIVO , 1970, Photochemistry and photobiology.

[78]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[79]  R. Wood.  DNA repair in eukaryotes. , 1996, Annual review of biochemistry.

[80]  D. Bishop,et al.  Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.

[81]  A. Chott,et al.  Mutations in apoptosis genes: a pathogenetic factor for human disease. , 2001, Mutation research.

[82]  J. Streilein,et al.  SALT: Skin-Associated Lymphoid Tissues , 1983 .

[83]  W. Morison.  In vivo effects of psoralens plus longwave ultraviolet radiation on immunity. , 1984, National Cancer Institute monograph.

[84]  L. Goldsmith.  Current problems in dermatology , 1988 .

[85]  J. Mandel,et al.  Incidence of skin carcinoma after renal transplantation. , 1977, Archives of dermatology.

[86]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[87]  Y. Kubo,et al.  Mutations of the INK4a locus in squamous cell carcinomas of human skin. , 1997, Biochemical and biophysical research communications.

[88]  R. Stern,et al.  Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. , 1997, The New England journal of medicine.

[89]  William D. Foulkes,et al.  The CDKN2A (p16) Gene and Human Cancer , 1997, Molecular medicine.

[90]  S. Tornaletti,et al.  UV damage and repair mechanisms in mammalian cells , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[91]  B. Berne,et al.  PUVA and cancer risk: the Swedish follow‐up study , 1999, The British journal of dermatology.

[92]  A. Schothorst,et al.  “High single‐dose’ European PUVA regimen also causes an excess of non‐melanoma skin cancer , 1991, The British journal of dermatology.

[93]  O. Larkö,et al.  Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. , 1982, Acta dermato-venereologica.

[94]  H. Studniberg,et al.  PUVA, UVB, psoriasis, and nonmelanoma skin cancer. , 1993, Journal of the American Academy of Dermatology.

[95]  S. George.  Adverse effects with PUVA and UVB phototherapy , 2001, The Journal of dermatological treatment.

[96]  R. Stern.  Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. , 1990, The New England journal of medicine.

[97]  T. Yagi,et al.  Mutations in ras genes in cells cultured from mouse skin tumors induced by ultraviolet irradiation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[98]  M. Kripke,et al.  Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Pittelkow,et al.  Incidence of skin cancers in patients with atopic dermatitis treated with coal tar: A 25-year follow-up study , 1980 .

[100]  W. Pierceall,et al.  N-ras mutation in ultraviolet radiation-induced murine skin cancers. , 1992, Cancer research.

[101]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[102]  K. Danno.  PUVA therapy: current concerns in Japan. , 1999, Journal of dermatological science.

[103]  L. Austin,et al.  312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of  T Cells within Psoriatic Lesions , 1999, The Journal of experimental medicine.

[104]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.